Skip to Main Content

Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Screening for Early Pancreatic Neoplasia (Cancer of the Pancreas Screening or CAPS4 Study) (CAPS4)

This study has been completed.

Sponsor:

Collaborators:

The V Foundation for Cancer Research

ChiRhoClin, Inc.

Information provided by (Responsible Party):

Sidney Kimmel Comprehensive Cancer Center

ClinicalTrials.gov Identifier:

NCT00714701

First received: July 9, 2008

Last updated: September 9, 2016

Last verified: September 2016

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	July 2016
Primary Completion Date:	July 2016 (Final data collection date for primary outcome measure)

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Eshleman JR, Norris AL, Sadakari Y, Debeljak M, Borges M, Harrington C, Lin E, Brant A, Barkley T, Almario JA, Topazian M, Farrell J, Syngal S, Lee JH, Yu J, Hruban RH, Kanda M, Canto MI, Goggins M. KRAS and guanine nucleotide-binding protein mutations in pancreatic juice collected from the duodenum of patients at high risk for neoplasia undergoing endoscopic ultrasound. Clin Gastroenterol Hepatol. 2015 May;13(5):963-9.e4. doi: 10.1016/j.cgh.2014.11.028. Epub 2014 Dec 4.

Kanda M, Sadakari Y, Borges M, Topazian M, Farrell J, Syngal S, Lee J, Kamel I, Lennon AM, Knight S, Fujiwara S, Hruban RH, Canto MI, Goggins M. Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia. Clin Gastroenterol Hepatol. 2013 Jun;11(6):719-30.e5. doi: 10.1016/j.cgh.2012.11.016. Epub 2012 Nov 28.